Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Waddah Arafat"'
Autor:
Rory M. Bade, Jennifer L. Schehr, Hamid Emamekhoo, Benjamin K. Gibbs, Tamara S. Rodems, Matthew C. Mannino, Joshua A. Desotelle, Erika Heninger, Charlotte N. Stahlfeld, Jamie M. Sperger, Anupama Singh, Serena K. Wolfe, David J. Niles, Waddah Arafat, John A. Steinharter, E. Jason Abel, David J. Beebe, Xiao X. Wei, Rana R. McKay, Toni K. Choueri, Joshua M. Lang
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2330-2344 (2021)
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous
Externí odkaz:
https://doaj.org/article/e1c2e50d818746e18a79e0890de7a105
Autor:
Xiaosong Meng, Murtaza Ahmed, Kevin D. Courtney, Waddah Arafat, Ibrahim Ibrahim, Vitaly Margulis, Craig Nichols, Aditya Bagrodia
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionPatients with advanced germ cell tumors (GCT) receiving cisplatin-based chemotherapy have high rates of thromboembolic events (TEE) which can negatively affect their overall survival. While primary TEE prophylaxis during chemotherapy may
Externí odkaz:
https://doaj.org/article/fdc22da99b7049d1b76096addad2f610
Autor:
Jonathan E. Schoenhals, BS, Osama Mohamad, MD, PhD, Alana Christie, MS, Yuanyuan Zhang, MD, PhD, Daniel Li, MD, Nirmish Singla, MD, MSCS, Isaac Bowman, MD, Waddah Arafat, MD, Hans Hammers, MD, Kevin Courtney, MD, PhD, Suzanne Cole, MD, Aditya Bagrodia, MD, Vitaly Margulis, MD, Neil Desai, MD, Aurelie Garant, MD, Hak Choy, MD, Robert Timmerman, MD, James Brugarolas, MD, PhD, Raquibul Hannan, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 5, Pp 100692- (2021)
Purpose: Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter- and intratumoral heterogeneity. We evaluated the effect of ste
Externí odkaz:
https://doaj.org/article/d3d6725df09840e68eee2bfa7aa552b3
Autor:
Raquibul Hannan, Michael Christensen, Alana Christie, Aurelie Garant, Ivan Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans Hammers, Waddah Arafat, Kevin Courtney, Isaac A. Bowman, David Sher, Chul Ahn, Suzanne Cole, Hak Choy, Robert Timmerman, James Brugarolas
Publikováno v:
Eur Urol Oncol
BACKGROUND: Evidence-based guidelines for the management of systemic therapy naïve oligometastatic renal cell carcinoma (RCC) are lacking. This prospective phase II single-arm trial evaluated the potential of stereotactic ablative radiotherapy (SAbR
Autor:
Jennifer R. Cracchiolo, Waddah Arafat, Ashish Atreja, Lauren Bruckner, Hamid Emamekhoo, Tricia Heinrichs, Ann C. Raldow, Jeffrey Smerage, Peter Stetson, Jessica Sugalski, Amye J. Tevaarwerk
Publikováno v:
Cancer.
Autor:
Raquibul Hannan, Michael Christensen, Hans Hammers, Alana Christie, Brendan Paulman, Dandan Lin, Aurelie Garant, Waddah Arafat, Kevin Courtney, Isaac Bowman, Suzanne Cole, David Sher, Chul Ahn, Hak Choy, Robert Timmerman, James Brugarolas
Publikováno v:
Eur Urol Oncol
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy sometimes progress at limited sites. The best treatment approach for patients with oligoprogression remains unclear. OBJECTIVE: To determine the ability of
Autor:
Shayna Simon, Lindsey Skelton, Sherry F. Parker, Rebecca Brian, Waddah Arafat, Muhammad Shaalan Beg
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:QIM22-203
Autor:
Serena K. Wolfe, David J. Beebe, Jamie M. Sperger, Jennifer L. Schehr, Erika Heninger, Toni K. Choueri, Xiao X. Wei, Joshua A. Desotelle, Charlotte N. Stahlfeld, Waddah Arafat, Joshua M. Lang, John A. Steinharter, Hamid Emamekhoo, Rana R. McKay, E. Jason Abel, Anupama Singh, Matthew C. Mannino, Tamara S. Rodems, David J. Niles, Rory M. Bade, Benjamin K. Gibbs
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2330-2344 (2021)
Molecular Oncology
Molecular Oncology
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous
Autor:
Waddah Arafat, Daniel B Martin, Tricia Heinrichs, Fernanda Polubriaginof, Jessica Sugalski, Travis J. Osterman, Amye J. Tevaarwerk, Jeffrey B. Smerage, Thevaa Chandereng
Publikováno v:
JCO Oncol Pract
PURPOSE: The use of telemedicine expanded dramatically in March 2020 following the COVID-19 pandemic. We sought to assess oncologist perspectives on telemedicine's present and future roles (both phone and video) for patients with cancer. METHODS: The
Autor:
Travis J. Osterman, Tricia Heinrichs, Daniel B Martin, Fernanda Polubriaginof, Waddah Arafat, Jessica Sugalski, Jeffrey B. Smerage, Amye J. Tevaarwerk
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:583-592
Introduction: The use of telemedicine in the oncology (Onc) setting expanded after March 2020 due to the COVID-19 pandemic. Patients and providers report satisfaction with telemedicine within the context of acute pandemic needs (Darcourt et al, JOP,